Eli Lilly and Company $LLY Shares Sold by Blue Fin Capital Inc.

Blue Fin Capital Inc. trimmed its holdings in Eli Lilly and Company (NYSE:LLY) by 5.2% in the first quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 10,075 shares of the company’s stock after selling 553 shares during the quarter. Eli Lilly and Company comprises 1.5% of Blue Fin Capital Inc.’s portfolio, making the stock its 15th largest holding. Blue Fin Capital Inc.’s holdings in Eli Lilly and Company were worth $9,267,000 as of its most recent SEC filing.

Several other large investors have also recently added to or reduced their stakes in the business. Maryland Capital Advisors Inc. bought a new position in shares of Eli Lilly and Company in the fourth quarter worth $25,000. Osbon Capital Management LLC bought a new stake in shares of Eli Lilly and Company during the fourth quarter valued at about $25,000. Basso Capital Management L.P. acquired a new stake in Eli Lilly and Company in the fourth quarter worth about $30,000. Maseco LLP grew its position in Eli Lilly and Company by 466.7% in the 1st quarter. Maseco LLP now owns 34 shares of the company’s stock valued at $31,000 after buying an additional 28 shares in the last quarter. Finally, E Fund Management Hong Kong Co. Ltd. grew its position in Eli Lilly and Company by 342.9% in the 4th quarter. E Fund Management Hong Kong Co. Ltd. now owns 31 shares of the company’s stock valued at $32,000 after buying an additional 24 shares in the last quarter. 82.53% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

LLY has been the topic of a number of recent analyst reports. Bank of America boosted their price target on shares of Eli Lilly and Company from $1,251.00 to $1,334.00 and gave the stock a “buy” rating in a research report on Friday, July 10th. Truist Financial increased their price objective on shares of Eli Lilly and Company from $1,281.00 to $1,370.00 and gave the company a “buy” rating in a report on Wednesday, July 8th. UBS Group raised their price objective on shares of Eli Lilly and Company from $1,250.00 to $1,425.00 and gave the company a “buy” rating in a research note on Monday, July 13th. Royal Bank Of Canada boosted their target price on Eli Lilly and Company from $1,250.00 to $1,500.00 and gave the stock an “outperform” rating in a report on Wednesday, July 8th. Finally, BMO Capital Markets restated an “outperform” rating on shares of Eli Lilly and Company in a research report on Monday, June 15th. Two research analysts have rated the stock with a Strong Buy rating, twenty-four have given a Buy rating, four have issued a Hold rating and one has given a Sell rating to the stock. According to MarketBeat.com, Eli Lilly and Company has a consensus rating of “Moderate Buy” and an average price target of $1,283.64.

Eli Lilly and Company News Summary

Here are the key news stories impacting Eli Lilly and Company this week:

• Positive Sentiment: Lilly continues to pull ahead of Novo Nordisk in the rapidly expanding obesity-treatment market, with significantly stronger recent revenue growth and a more favorable outlook. Lilly’s latest reported quarter included 55.5% year-over-year revenue growth, while Novo Nordisk expects an adjusted sales decline. Eli Lilly Stock Has Skyrocketed. Novo Nordisk Has Crashed.
• Positive Sentiment: The company is investing another $750 million with Resilience to expand U.S. manufacturing capacity for diabetes and obesity medicines. The project is expected to add at least 400 jobs and supports Lilly’s ability to meet continued demand. Lilly Boosts Diabetes and Obesity Capacity With $750 Million Deal
• Positive Sentiment: Completion of a late-stage retatrutide trial provides a potential future catalyst in diabetes, obesity and related cardiovascular indications. Lilly has also begun an early-stage study of eloralintide, adding another candidate to its weight-loss pipeline. Lilly’s Retatrutide Trial Completion Signals Next Wave in Diabetes and Obesity Drugs
• Neutral Sentiment: Analysts are focused on key operating metrics for Lilly’s second-quarter results, including demand, prescription trends and guidance. The company’s prior earnings report substantially exceeded estimates, raising expectations for the upcoming release. Lilly Q2 Earnings on the Horizon
• Negative Sentiment: Weight-loss drug stocks came under pressure as investors digested clinical-trial news and positioned ahead of earnings. Technical selling intensified after Lilly fell below a closely watched support level, despite its stronger long-term fundamentals. Weight Loss Drug Stocks Slump

Eli Lilly and Company Price Performance

Shares of NYSE LLY opened at $1,149.28 on Friday. Eli Lilly and Company has a twelve month low of $623.78 and a twelve month high of $1,249.45. The company has a current ratio of 1.50, a quick ratio of 1.10 and a debt-to-equity ratio of 1.26. The company has a market capitalization of $1.08 trillion, a price-to-earnings ratio of 40.83, a PEG ratio of 1.43 and a beta of 0.51. The firm has a 50-day moving average of $1,152.66 and a two-hundred day moving average of $1,044.16.

Eli Lilly and Company (NYSE:LLY) last posted its quarterly earnings data on Thursday, April 30th. The company reported $8.55 earnings per share for the quarter, beating the consensus estimate of $6.97 by $1.58. The company had revenue of $19.80 billion during the quarter, compared to analyst estimates of $17.82 billion. Eli Lilly and Company had a net margin of 34.98% and a return on equity of 105.77%. The business’s revenue for the quarter was up 55.5% on a year-over-year basis. During the same quarter last year, the firm posted $3.34 EPS. As a group, analysts expect that Eli Lilly and Company will post 34.91 earnings per share for the current fiscal year.

Eli Lilly and Company Announces Dividend

The firm also recently announced a quarterly dividend, which will be paid on Thursday, September 10th. Investors of record on Friday, August 14th will be issued a dividend of $1.73 per share. This represents a $6.92 dividend on an annualized basis and a yield of 0.6%. The ex-dividend date is Friday, August 14th. Eli Lilly and Company’s dividend payout ratio (DPR) is presently 24.58%.

Eli Lilly and Company Company Profile

Eli Lilly and Company (NYSE: LLY) is a global pharmaceutical company founded in 1876 and headquartered in Indianapolis, Indiana. The company researches, develops, manufactures and commercializes a broad range of medicines and therapies for patients worldwide. Eli Lilly maintains operations and commercial presence across North America, Europe, Asia and other regions, serving both developed and emerging markets. The company has been led in recent years by President and Chief Executive Officer David A.